All In Biotech

Drug Trial Radar · NCT06126224

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 28, 2023

Primary completion

Dec 9, 2026

Study completion Dec 9, 2026

Sponsor

Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

Conditions

  • Psychosis Associated With Alzheimer's Disease

Interventions

  • KarXTDrug

    KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)

  • PlaceboDrug

    Placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) scoreTime frame: Baseline and end of Treatment (up to 14 Weeks)

Locations

157 sites in 14 countries. Site status is shown where the registry gives one.

  • Local Institution - 1116

    Chandler, Arizona · Active not recruiting

  • Local Institution - 1044

    Phoenix, Arizona · Active not recruiting

  • Local Institution - 1104

    Anaheim, California · Active not recruiting

  • Local Institution - 1119

    Canoga Park, California · Active not recruiting

  • Local Institution - 1151

    Encino, California · Active not recruiting

  • Local Institution - 1142

    Lancaster, California · Active not recruiting

  • Local Institution - 1117

    Los Alamitos, California · Active not recruiting

  • Local Institution - 1103

    Sherman Oaks, California · Active not recruiting

  • Local Institution - 1007

    Walnut Creek, California · Active not recruiting

  • Local Institution - 1160

    Apopka, Florida · Withdrawn

  • Local Institution - 1156

    Clermont, Florida · Active not recruiting

  • Local Institution - 1138

    Cutler Bay, Florida · Active not recruiting

  • Local Institution - 1162

    Delray Beach, Florida · Active not recruiting

  • Local Institution - 1164

    Doral, Florida · Active not recruiting

  • Local Institution - 1165

    Fort Myers, Florida · Active not recruiting

  • Local Institution - 1155

    Hialeah, Florida · Active not recruiting

  • Local Institution - 1107

    Hialeah, Florida · Active not recruiting

  • Local Institution - 1120

    Hialeah, Florida · Active not recruiting

  • Local Institution - 1140

    Hialeah, Florida · Active not recruiting

  • Local Institution - 0150

    Homestead, Florida · Active not recruiting

  • Local Institution - 1145

    Homestead, Florida · Active not recruiting

  • Local Institution - 1127

    Largo, Florida · Active not recruiting

  • Local Institution - 1039

    Maitland, Florida · Active not recruiting

  • Local Institution - 1146

    Maitland, Florida · Active not recruiting

  • Local Institution - 1159

    Miami, Florida · Active not recruiting

  • Local Institution - 1118

    Miami, Florida · Active not recruiting

  • Local Institution - 1111

    Miami, Florida · Active not recruiting

  • Local Institution - 1108

    Miami, Florida · Active not recruiting

  • Local Institution - 1125

    Miami, Florida · Active not recruiting

  • Local Institution - 1115

    Miami, Florida · Active not recruiting

  • Local Institution - 1143

    Miami, Florida · Active not recruiting

  • Local Institution - 1113

    Miami, Florida · Active not recruiting

  • Local Institution - 1009

    Miami, Florida · Active not recruiting

  • Local Institution - 1129

    Miami, Florida · Active not recruiting

  • Local Institution - 1150

    Miami, Florida · Active not recruiting

  • Local Institution - 1109

    Miami, Florida · Active not recruiting

  • Local Institution - 1158

    Miami, Florida · Active not recruiting

  • Local Institution - 1147

    Miami, Florida · Active not recruiting

  • Local Institution - 1105

    Miami, Florida · Active not recruiting

  • Local Institution - 1157

    Miami, Florida · Active not recruiting

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.